Latest Updates Around The World
Drug giant Sun Pharmaceutical Industries on Wednesday reported a net profit after tax of Rs 3,117.95 crore for the second quarter of FY26, a growth of 2.6% year-on-year compared to a profit of Rs 3,040.16 crore in the year-ago period.The company said operating revenue for the second quarter ended September 2025 stood at Rs 14,405.22 […]
Sun Pharma is expected to show steady but moderate growth in its September second quarter (Q2 FY26) earnings, with analysts highlighting a combination of factors: a high base effect from last year’s Revlimid sales, weak performance at Taro and early-stage spending on the US launch of Leqselvi, the recently approved specialty drug.According to average broker […]
